Two new studies from MIT and Harvard Medical School, focusing on a cytokine called IL-17, now add to that evidence. The researchers found that IL-17 acts on two distinct brain regions—the amygdala and ...

The risk for inflammatory bowel disease is higher in patients with psoriasis or ankylosing spondylitis using IL-17A inhibitors than in those using apremilast, necessitating careful patient monitoring.

UCB has been bringing up the rear in the IL-17 inhibitor category with bimekizumab, but now has EU approval for the drug and thinks it can mount a stiff challenge to the leaders, including ...

The interleukin-17 (IL-17) family cytokines are strong inducers of inflammation and help to protect us against invading pathogens. However, they also have a dark side and contribute to the tissue ...

Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, so is celebrating new late-stage data showing superiority to the class leader.

Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and more frequent adverse events. The study used the Dutch BioCAPTURE ...

IL-17 acts on the amygdala to increase anxiety and on the somatosensory cortex to enhance sociability. This suggests a close connection between the immune and nervous systems.